Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 15/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 11/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 11/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.48 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.48 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.48 |
| ▸ | GOT1 | P17174 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3753450 | 0.88 | KMT2A (0.54) | — | |
| SCHEMBL3745745 | 0.88 | FAAH (0.48) | — | |
| SCHEMBL3960964 | 0.85 | SCN9A (0.70) | SCN9ASCN5AKCNH2KCNQ2KCNA5 | |
| SCHEMBL3754052 | 0.84 | SIRT1 (0.52) | SCN9ASCN5AKCNH2 | |
| SCHEMBL3745544 | 0.82 | MTNR1A (0.49) | — | |
| SCHEMBL3759925 | 0.82 | KCNA5 (0.56) | SCN9ASCN5AKCNH2KCNQ2KCNA5 | |
| SCHEMBL3754846 | 0.81 | CDK4 (0.52) | SCN9ASCN5AKCNH2GOT1 | |
| SCHEMBL3755256 | 0.80 | POLB (0.61) | SCN9AKCNH2 | |
| SCHEMBL3750239 | 0.80 | SCN9A (0.51) | SCN9ASCN5AKCNH2KCNQ2KCNA5 | |
| SCHEMBL3754277 | 0.80 | MEN1 (0.51) | KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| EP-2049484-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008008022-A1 | ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | WO | disclosed |
| US-20080015237-A1 | NEW COMPOUNDS I/418 | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015237-A1 | NEW COMPOUNDS I/418 | KCNH1, KCNH2, KCNH3 | SCN9A 119/4885SCN5A 48/4885KCNH2 2/4885 |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | KCNH1, KCNH2, KCNQ2 | SCN9A 177/4885SCN5A 26/4885KCNH2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.